logo
logo

Day Zero Diagnostics Doubles Down on epiXact® Service for Investigating Healthcare-Associated Infection Outbreaks Supported by New NIH Funding Award

Dec 09, 2020•over 4 years ago
Boston

Description

Day Zero Diagnostics, Inc., an infectious disease diagnostics company harnessing the power of whole-genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, today announced it has received a Phase I Small Business Innovation Research (SBIR) award from the National Institute of Allergies and Infectious Disease (NIAID) of the National Institutes of Health (NIH).

Company Information

Company

Day Zero Diagnostics

Location

Boston, Massachusetts, United States

About

Day Zero Diagnostics, Inc., based in Boston, is pioneering a new class of infectious disease diagnostics using whole-genome sequencing and machine learning to revolutionize how the world fights the growing threat of antibiotic resistance. The company's mission is to change the way infectious diseases are diagnosed and treated by rapidly identifying both the species and the antibiotic resistance profile of severe infections without the need for a culture. By using sequencing, Day Zero also enables big data approaches for managing healthcare-associated infection outbreaks. Day Zero Diagnostics was founded in 2016 by a team of clinicians and scientists from Harvard University and Massachusetts General Hospital. The company has been recognized as a leading innovator by CARB-X, UCSF Health, American Association of Clinical Chemistry, MedTech Innovator, TedMed Hive, Xconomy, HealthTech Arkansas, and MassChallenge HealthTech. For more information visit www.dayzerodiagnostics.com or follow us on Twitter at @dayzerodx and LinkedIn at https://www.linkedin.com/company/day-zero-diagnostics-inc/.